Table 47Survival outcomes: DEB compared with TAE, case series studies

Study
Rating
Group
N
InterventionSurvival Time FromMedian OS (95% CI)% Survival Year 1% Survival Year 2% Survival Year 3% Survival Year 4% Survival Year 5
Martin et al. 201185
Poor
DEB
118
DEB with doxorubicin (75 mg per 2 mL, minimum recommended volume of 10 mL) in 2 bead vials via hepatic artery every 3–8 weeks for 2–4 treatment cyclesNot reported14.275NRNRNRNR
Seki et al. 201180
Poor
DEB
135
TACE with epirubicin-loaded (25–30 mg) superabsorbent polymer microspheres via hepatic arteryStudy treatment2673.759.0NRNRNR
Rand et al. 200579
Good
TAE
46
TAE with tirsacryl gelatin microspheres (size 100–700 μ) followed by cyanoacrylate (0.3–1 mL) and lipiodol via hepatic arteriesHCC diagnosis22.270.7NRNRNRNR

Abbreviations: CI = confidence interval; DEB = drug-eluting beads; HCC = hepatocellular carcinoma; N = number of patients; NR = not reported; NS = nonsignificant; OS = overall survival; TACE = transarterial chemoembolization; TAE = transarterial alcohol embolization.

From: Results

Cover of Local Therapies for Unresectable Primary Hepatocellular Carcinoma
Local Therapies for Unresectable Primary Hepatocellular Carcinoma [Internet].
Comparative Effectiveness Reviews, No. 114.
Belinson S, Yang Y, Chopra R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.